Protocol for systematic review of evidence on the determinants and influence of early glycaemic control in childhood-onset type 1 diabetes by Mazarello Paes, V et al.
Mazarello Paes et al. Systematic Reviews  (2015) 4:159 
DOI 10.1186/s13643-015-0146-8PROTOCOL Open AccessProtocol for systematic review of evidence
on the determinants and influence of early
glycaemic control in childhood-onset type
1 diabetes
Veena Mazarello Paes1,2*, Dimitrios Charalampopoulos1, Amal R. Khanolkar1,3, David Taylor-Robinson1,4,
Russell Viner1, Julie Edge5, Terence Stephenson1 and Rakesh Amin1Abstract
Background: Landmark studies in adult-onset type 1 diabetes (T1D) populations indicate that improved glycaemic
control through use of intensive insulin therapy is strongly associated with reduced risk for the development of
diabetes-related complications and mortality in later years. However, it is unclear whether these associations can be
extrapolated to childhood-onset T1D, given the influence of other important biological and psychosocial determinants
of glycaemic control, particularly during adolescence. The aims of the review are (1) to investigate the impact of early
glycaemic control (within the first 2 years after diagnosis) on subsequent glycaemic trends and risk of complications
during the life course of childhood-onset T1D and (2) to identify the predictors of early glycaemic control in children
and young people (0–25 years).
Methods: The methods used in this study are systematic identification, review and mapping of quantitative
(intervention and observational) and qualitative literature; assessing the effect and predictors of early glycaemic
control in T1D (diagnosed ≤18 years) on risk or prevalence of later complications. An iterated search strategy,
with no language or period restrictions, was applied to identify studies from six electronic databases. This will be
supplemented by hand-searching (reference lists and contacting authors of studies meeting the inclusion
criteria). Studies assessing glycaemic control within the first 2 years of diagnosis in children (at baseline) will be
quality-assessed against predefined criteria and mapped descriptively to future health outcomes. Extracted data
will be analysed and synthesised using narrative and forest plots or harvest plots for quantitative evidence and
thematic analyses for qualitative studies. To get a deeper understanding of the predictors of early glycaemic
control in reducing complications in childhood and adult life, we will integrate qualitative and quantitative
evidence using mixed methods or parallel synthesis approach.
Discussion: These linked reviews will be the first to systematically investigate the effects of early glycaemic
control and integrate both the quantitative and qualitative evidence on predictors of early glycaemic control in
childhood-onset T1D in reducing future diabetes complications. This will help identify and map current research
and inform development of effective future interventions.
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Recent studies indicate a reduction of life expectancy by
over a decade, in people diagnosed with type 1 diabetes
(T1D) [1–3]. Given the duration of glycaemic exposure,
the risk for diabetes-related vascular diseases is likely to
be greater in childhood-onset compared to adult-onset
T1D [3–6]. The burden of T1D greatly impacts upon the
quality of life of children and their families [7, 8]. These
poor outcomes have been highlighted by health policy ad-
visers [9] and are of relevance given the increasing world-
wide incidence of childhood T1D [10–14], and in those
aged under 5 years, in whom both prognosis and burden
of disease are likely to be even worse [15–18]. The stron-
gest modifiable predictor of complications in T1D patients
is glycaemic control, which is measured as haemoglobin
A1c levels (HbA1c) [19–22]. Use of intensive insulin ther-
apy in young children is associated with better glycaemic
control (i.e. lower HbA1c levels) [23].
Results from a recent systematic review of 18 clinical
trials (with a total of 2254 T1D participants and a mean
follow-up duration across studies varying between 1 and
25 years) showed that targeting intensive glycaemic con-
trol (four or more insulin injections per day or insulin
pump therapy) did not improve all-cause mortality, but
it reduced the relative risk of the composite macrovascu-
lar outcomes (0.63; confidence interval (CI) 0.41 to 0.96;
P = 0.03) and diabetic nephropathy (0.37; CI 0.27 to 0.50;
P < 0.00001), when compared to management with con-
ventional insulin regimens (i.e. three or less insulin in-
jections per day) [24]. However, the review could not
assess the effect of targeting intensive glycaemic control
on patients younger than 18 years and no macrovascular
or microvascular outcomes were reported in the four
small trials (sample sizes between 14 and 34), three of
which included newly diagnosed T1D patients under
18 years, probably due to the short follow-up period of
up to 1.5 years [25–28].
An updated Cochrane review with 12 trials (with a
mean follow-up duration across studies varying between
1 and 6.5 years) concluded that tight glycaemic control
(compared to less intense treatment targets) was benefi-
cial in younger patients (age not specified), at early
stages of disease (retinopathy: RR 0.27 (95 % CI 0.18 to
0.42); P < 0.00001; nephropathy: RR 0.56 (95 % CI 0.46
to 0.68); P < 0.00001; neuropathy: RR 0.35 (95 % CI 0.23
to 0.53); P < 0.00001) [29]. However, this review con-
tained just one trial in young children aged 6–15 years
with diabetes duration of 1–2 years [30], and most of
the other included trials were conducted in the 1980s,
when use of insulin pump therapy was less widespread.
Also, evidence from landmark studies indicates that
improved glycaemic control in T1D through use of inten-
sive insulin therapy is strongly associated with reduced
complications risk and mortality [19, 31, 32]. Results fromthe Diabetes Control and Complications Trial (DCCT), a
multicenter, randomised controlled clinical trial of 1441
people (including 195 adolescents) with T1D (1983–1993),
provided evidence that early intensive glycaemic control
conferred a significant reduction in risk of microvascular
and macrovascular complications compared to conven-
tional treatment, an effect which continued in subsequent
years even after equalisation of metabolic control [21, 31,
33, 34]. Importantly, reduced mortality was also observed
with the use of early intensive versus conventional insulin
therapy use (43 deaths versus 64 deaths respectively
among 1429 participants; hazard ratio 0.67 (95 % CI
0.46–0.99)) after 27 years from entry into the trial [31].
All-cause mortality was significantly higher among those
with higher mean HbA1c levels (hazard ratio (HR) = 1.56
(95 % CI 1.35–1.81 per 10 % relative increase in HbA1c);
P < 0.001) and with renal disease (HR = 8.51(95 % CI
4.45–16.27); P < 0.001) during the 27-years of follow-
up [33, 35].
Other studies have also suggested the beneficial effects
of early glycaemic control in preventing future complica-
tions [36, 37]. Therefore, it appears that maintaining
lower HbA1c levels in the early years after diagnosis may
be beneficial in adults for reducing future risk of compli-
cations, regardless of subsequent glycaemic control over
the course of diabetes duration. Diabetologists use the
term “metabolic memory” for these observations. How-
ever, the DCCT contained only 195 adolescents (13 to
17 years of age at entry), with T1D duration of 38 ±
20 months at the start of the trial [38]. Hence, the effect
of insulin intensification from or near to diagnosis has
not been robustly assessed in childhood-onset T1D. It
would be important to note that adult outcomes cannot
be extrapolated to childhood due to important biological
and psychosocial determinants such as puberty, insulin
resistance and adolescent risk-taking behaviours that are
less relevant in adults [39].
Furthermore, some reports indicate that very early
HbA1c level track with future glycemic control, i.e. low
or high HbA1c levels within the first few months of diag-
nosis associate with low or high HbA1c levels in later
years, an effect which can persist for almost a decade
[31, 40–43]. These studies were from USA and Europe, but
the age range, duration of T1D, treatment and follow-up
varied across studies. Additionally, the use of intensive
insulin therapy in early childhood T1D is increasing
but is not universal [44]. Also, many well-documented
population-based registries lack robust and comparable
data on glycemic control [45].
Our review will investigate whether HbA1c levels in
the first 2 years following diagnosis of T1D in children
predicts future risk of complications and will quantify
the extent to which the level of glycaemia in the first
2 years of diabetes tracks in adulthood/with increasing
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of early glycaemic control and how these may influence
the paediatric TID management plan. Our analyses may
highlight a need for a change in early care processes in
children with T1D, by providing an argument for more in-
tensive diabetes treatments than are currently undertaken.Methods/study design
We will undertake two linked systematic reviews answering
two main research questions, namely:
1. Is higher early HbA1c (within 2 years of T1D
diagnosis) associated with later complications in
child-onset T1D patients (childhood-onset T1D
defined as onset ≤18 years)?
2. What factors at diagnosis or soon after are
associated with higher early HbA1c?
We will follow the methods for conducting systematic
reviews, as described by the Evidence for Policy and
Practice Information (EPPI) and Co-ordinating Centre
[46]. The review process will be in four phases. Phase
1 (completed): iterative scoping stage to define the re-
search question, refine the search strategy and outline the
inclusion/exclusion and quality assessment criteria. This
was followed by identification of literature by searching of
electronic databases. Phase 2: descriptive mapping and
synthesis of existing evidence by number, types and quality
attributes of research studies on the topic. Phase 3: de-
tailed data extraction and in-depth synthesis of quantita-
tive studies [47]. Phase 4: thematic analysis of qualitativeTable 1 Search strategy for research questions: Does early glycaemi
childhood-onset T1D have an impact on subsequent risk of complic
of early glycaemic control?
Population Exposure
Childhood or paediatric onset diabetes or
juvenile diabetes diagnosis or newly diagnosed
children or young persons or young people or
children or young or adolescent or teen or
youth or adult T1D patient or type 1 diabetes or
T1D or type 1 diabetes mellitus or T1DM or
DM1 or type 1 or IDDM or insulin dependent or
non-insulin dependent or childhood onset diabetes
or childhood onset T1D or auto-immune or
autoimmune or sudden onset or uncontrolled
or labile or brittle
Early diabetes control or H
HbA1c trends or glycaemi
glycosylated or HbA1c or
or HbA(1c) level or glycae
control or diabetes contro
intervention or intensive o
standard or regular or opt
or strict control or usual o
treatment or intervention
insulin use or injection or
or intensive therapy or insliterature [48], followed by integration of these findings
with the quantitative evidence by using parallel synthesis
or mixed method approach [49]. This methodology of
using qualitative research to explain quantitative evidence
will provide a deeper understanding of the predictors in-
fluencing early glycaemic control in children and young
people.Search strategy
After a number of initial iterative scoping searches, with
input from experts in the field, the search strategy was
refined to maximise sensitivity and specificity in capturing
key publications. Three sets of search terms were used
(see search strategy in Table 1) relating to population
(children and young people diagnosed with TID), exposure
(terms to capture observational, intervention, qualitative
studies and review articles relating to early diabetes con-
trol) and outcome (complications, mortality or metabolic
memory).
Six electronic databases (Medline and Embase (via
OVID), Web of Science (via Thomson Reuters), Cinhal
(via EBSCO), Scopus (via Elsevier) and Cochrane Library)
were double-searched in parallel (by VMP and HC to min-
imise study selection bias) in December 2014, without time
period or language restrictions, by using a combination of
free text and Thesaurus or Mesh terms (see Additional file
1: Electronic database search strategy.pdf ). All identified
articles from individual databases (Medline, n = 13,039;
Embase, n = 645; Web of Science, n = 2323; Cinahl, n = 984;
Scopus, n = 1540 and Cochrane, n = 3242) were imported
into an endnote file and de-duplicated, which resulted inc control (intervention within two years post diagnosis) in
ations in childhood and adulthood? What are the predictors
Outcome
bA1c trajectories or
c trajectories or
A1c or Hemoglobin A
mic control or glucose
l or early intensive
r conventional or
imised or tight control
r routine or therapy or
or management or
dose insulin injections
ulin pump
Diabetic or diabetes complications or
complications or side effects or adverse events
or acute complications or chronic complications
or glycaemia or hyper glycaemia or hypo
glycaemia or ketosis or diabetic ketoacidosis or
DKA or nonketotic hyperosmolar coma or
insulin resistance or autoimmune disease or
urine albumin or urine albumin creatinine ratio
or urine albumin excretion or microalbuminuria
or macroalbuminuria or renal disease or diabetic
nephropathy or nephropathy or dialysis or foot
ulcer or amputation or retinopathy or blindness
or vascular disease or vascular complications or
microvascular disease or microvascular
complications or macrovascular disease or
macrovascular complications or cardiovascular
disease or MI or myocardial infarction or stroke
or coronary artery disease or cerebrovascular
disease or peripheral vascular disease or blood
pressure or BP or statin or death or mortality or
Pathology or metabolism or metabolic memory
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mented by hand-searching reference lists and contacting
authors of included studies and relevant reviews (see Fig. 1
for a flow diagram of the study selection process).Inclusion and exclusion criteria
Interventional studies, i.e. randomised control trials (RCTs)
and non-RCTs, targeting glycaemic control (within 2 years
of diagnosis of T1D in children and young people) and
describing an association with health outcomes will be
included. Observational, i.e. cohort and cross-sectional
studies that quantified the association between early gly-
caemic control (within 2 years of diagnosis of T1D) AND
risk of future complications in children and young people
aged 0 to 25 years at baseline, will be included. Qualitative
studies that give a deeper background understanding
on the predictors of early HbA1c in this age group will
also be included.
Our exclusion criteria are as follows: non-human or
animal studies, studies with population selected for other
diseases/co-morbidities or clinical conditions, studies in
adults aged more than 25 years at baseline, studies in
other types of diabetes such as type 2 diabetes (T2D) or
gestational diabetes. Quantitative studies not reporting
clinical outcomes or quantitative studies that measuredFig. 1 Flowchart presenting an overview of the search resultsglycaemic control but did not describe an association with
outcome variables will also be excluded. The overlapping
eligibility criteria for the reviews are presented as inclu-
sion/exclusion criteria in Table 2.Study selection procedure
A 10 % proportion (1792) of the total abstracts and titles
will be randomly selected and double screened (DC and
VMP), based on a piloted screening protocol. Results
will be compared to ensure less than 5 % discrepancy
between reviewers. Any disagreements will be resolved
through discussion and re-examining of abstract. Follow-
ing which, all 17,915 abstracts and titles will be screened
independently (VMP). Full texts of abstracts appearing
to meet the inclusion criteria will be ordered for further
review and data extraction. Descriptive mapping of exist-
ing evidence will be undertaken to establish gaps in
evidence-base and to ascertain that there is sufficient
data meriting review.
Data extraction and quality assessment
A data extraction Excel spread sheet will be piloted to
ensure consistency of data extraction between reviewers.
One of the reviewers (VMP) will then systematically re-
view and extract detailed data of all studies meeting the
Table 2 Inclusion and exclusion criteria for review of evidence on the following: 1. Does early HbA1c predict later complications?
2. What factors predict early HbA1c?
Inclusion criteria Exclusion criteria
For reviews 1 and 2
Interventional studies (RCT’s and non-RCT’s) targeting glycaemic control (within
2 years of diagnosis of T1D) and described an association with health outcomes
Non-human studies
Selection of population based on other diseases/co-morbidities
Adults aged more than 25 years at baseline
Studies on T2D
Quantitative studies not reporting clinical outcomes
Quantitative studies that measured glycaemic control but did not
describe an association with outcome variables
Non-intervention/observational, i.e. cohort and cross-sectional (XS) studies
that quantified the association between early glycaemic control (within 2 years
of diagnosis of T1D) AND risk of future complications in children and young
people aged 0 to 25 years at baseline
For review 1: longitudinal studies with a follow-up of ≥5 years from diagnosis
For review 2: qualitative studies that give a deeper background understanding
on the topic
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double-reviewed by a second reviewer, and any differ-
ences will be discussed and resolved. Details of data will
be extracted according to study designs, i.e. interven-
tional, observational and qualitative (see Table 3).
Included studies will be systematically quality-assessed
against pre-set quality criteria by using standard quality
assessment checklists designed by the EPPI centre for
specific (intervention, observational and qualitative) study
designs (see Table 4).
Data syntheses
Extracted data will be analysed and synthesised using a
narrative and either forest plots or harvest plots (for
quantitative evidence) and thematic analyses (for qualitative
studies). To get a deeper understanding of the predictors
of early glycaemic control in reducing complications in
childhood and adult life, we will integrate qualitative and
quantitative evidence using mixed methods or parallel
synthesis approach.
Intervention studies
Meta analyses will be attempted to synthesise data from
RCTs and Non-RCTs, assessed with low risk of bias and
the results presented as forest plots [50]. Subgroup ana-
lyses by intervention type will be undertaken, subject to
data type and quality.
Observational studies
Harvest plots [51] will be used to summarise data if
meta-analysis/meta-regression is not possible. The evi-
dence will be presented as bar charts and symbols. Colour
(black, dark grey and light grey) of bar will representquality of study, with lighter bars representing studies of
low quality. Height of bar will indicate the study size, and
position of the bar will summarise the direction and
strength of the association (++, +, 0, −, −−). Categorical
and continuous outcome variable results will be consist-
ently recoded, such that a single or double + symbolises
higher risk for complications, and a single or double −
symbolises a lower risk for complications [52, 53].Qualitative studies
Evidence from qualitative studies will be synthesised
thematically, and the results will be integrated with the
quantitative evidence using the parallel synthesis or
mixed methods approach [54, 55]. Recommendations
for future interventions and policy decisions will be drawn
by interpreting quantitative findings, using the themes
identified from qualitative studies.Discussion
The importance of diabetes-related complications may
be underestimated. Data from the 2010–2011 National
Paediatric Diabetes Audit (NPDA) showed that only
5.8 % of all children and young persons with diabetes
are recorded as having received all the National Institute
for Health and Care Excellence (NICE) recommended
care processes aimed at reducing risk of chronic compli-
cations [56]. This percentage increased to 16.1 % in the
2013–2014 NPDA, which may reflect the incentivising
effect of the recent introduction of the best practice tariff
for paediatric diabetes care in the UK [57]. However, this
percentage of optimum service delivery still compares
Table 3 Details of data extracted for different study designs
Intervention studies Observational/non-intervention studies
(cross-sectional and prospective)
Qualitative studies
Study id Study id Study id
Author Author Author
Year Year Year
Country Country Country
Age range Age range Age
Average age Average age Design
Sex (male to female ratio) Sex (male to female ratio) Number of
participants
Design: cRCT, RCT, quasiRCT, before-after, etc. Ethnicity Sample/recruitment
Number of participants Socioeconomic status Findings/direct
quotes
Sample/recruitment, e.g. general population representative sample or
specialist groups (deprivation, ethnicity, geography, etc.)
Design (cross-sectional/prospective) Author conclusions
Intervention details (pump/injection, duration, dosage) Number of participants Comments
Control Sample/recruitment, e.g. general population
representative sample or specialist groups
Author email
Setting (home, primary care, secondary care) Exposure examined
Intervention provider Measurement of exposure
Number of sites Measurement conducted by Level of glycemic control
Outcome (complications, metabolic memory—separate row for each
outcome investigated)
Setting (home, primary care, secondary care)
Measurement of outcome (objective) Outcome (complications, metabolic
memory—separate row for each outcome
investigated)
Analysis Measurement of outcome (objective)
Effect—point estimate Analysis
Effect—upper confidence interval
Effect—lower confidence interval
Follow-up duration Effect
Comments Author email
Author email Comments
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recommended care processes during the 2011–2012
and 2012–2013 National Diabetes Audits (NDA)) and
is very low when compared internationally [16, 58].
In a clinic setting, aiming for tight glycaemic targets
remains difficult to achieve, outside of a clinical trial. The
mean HbA1c level in the intensively treated group partici-
pating for more than 20 years ago in the DCCT was lower
than the HbA1c levels in most patients today [59, 60]. The
intensive group achieved HbA1c levels of 7 % on an average
compared with 8.3 % among more than 25,000 patients
from 67 US centres in the T1D exchange [59], and this was
achieved without modern advances in therapy, such as
insulin analogues and continuous glucose monitors.
Therefore, we need to understand the effect, predictorsand trends of early glycaemic control on complications
risk in childhood and adults.
Our second aim is to look at which factors predict
early HbA1c. These could be factors across the whole
biopsychosocial model. For example, there may be social
factors (deprivation, ethnic), psychological factors (teen-
age behaviour, fear of hypoglycaemia), physiological fac-
tors (glycation index) as well as wider cultural factors
(the family, school, clinic setting, etc.).
By systematically reviewing evidence on effect of gly-
caemic control within first 2 years of T1D diagnosis
and tracking with increasing diabetes duration, this will
help identify predictors of early glycaemic control and
understand future risk for complications in the paediatric
population.
Table 4 Quality assessment criteria by study design
For intervention studies For observational (prospective cohort and
cross-sectional) studies
For qualitative studies
Total quality assessment score (maximum of 8) was
derived for the fulfilment of following criteria:
Total quality assessment score (maximum
of 6) was derived for the fulfilment of
following criteria:
Total quality assessment score (maximum of
12) was derived for the fulfilment of
following criteria:
1) Randomisation 1) More than 50 participants analysed 1) Research questions clearly stated
2) Effect of intervention reported for all outcomes 2) Studies representing general population 2) Approach appropriate for the research
question
3) Pre-intervention data on all outcomes 3) Prospective study design 3) Qualitative approach clearly justified
4) Post-intervention data on all outcomes 4) Adjusted/multivariate analysis 4) Study context clearly described
5) Allocation concealment 5) Objective measure of outcome 5) Role of the researcher clearly described
6) Blinding 6) Objective measure of exposure 6) Sampling method clearly described
7) Objective measurement of outcome 7) Sampling strategy appropriate for the
research question
8) Retention >70 % 8) Method of data collection clearly
described
Studies with small sample size (n < 50) and no control
group were considered to provide lower quality evidence
and not scored
9) Data collection method appropriate
10) Method of analysis clearly described
11) Analysis appropriate for the research
question
12) Conclusions supported by sufficient
evidence
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children and young adults
To our knowledge, this is the first review to robustly in-
vestigate evidence on the association of early glycaemic
control in childhood-onset T1D with future complications
risk. Furthermore, this is the first review to rigorously and
systematically integrate quantitative (both intervention
and observational) and qualitative evidence on this topic
[55]. Evidence synthesised this way is holistic and more
reliable than syntheses of any one type of research in
isolation.Dissemination and updating plans
Results of the review will be disseminated through peer-
reviewed publications, conference presentations and at
meetings. The review will be updated if significant new
evidence becomes available.Additional file
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DCCT: Diabetes Control and Complications Trial; EPPI: Evidence for Policy
and Practice Information; HbA1c: glycated haemoglobin A1c; NDA: National
Diabetes Audit; NICE: National Institute for Health and Care Excellence;
NPDA: National Paediatric Diabetes Audit; PROSPERO: International
Prospective Register for systematic Reviews; RCT: randomised control trial;
T1D: type 1 diabetes.Competing interests
No potential conflict of interest was reported by the authors.
Authors’ contributions
VMP was the lead reviewer, created the study design and search strategy,
searched electronic databases for literature and wrote the first draft of the
protocol. RA conceptualised the project, was project lead, advised on the
trajectories of the project, participated in the study design and helped revise
the manuscript. DC double screened a proportion of titles/abstracts,
participated in the study design and helped revise the manuscript. ARK
participated in the design of the study and helped revise the manuscript.
DTR participated in the design of the study and helped revise the
manuscript. TS was overall project lead, advised on the trajectories of the
project, participated in the study design and helped revise the manuscript.
RV advised on the trajectories of the project, participated in the study design
and helped revise the manuscript. JE advised on the trajectories of the
project, participated in the study design and helped revise the manuscript.
All authors contributed to the study design, critical revision of the
manuscript and approved the final version.
Acknowledgements
Our sincere thanks to the funders and the following from the University
College London: Miss Heather Chester (HC) for her help with the literature
search strategy and Mrs Linda Haines for her help and support throughout.
The authors also thank the following collaborators for their comments and
guidance on the project: Prof. David Dunger, Department of Paediatrics,
University of Cambridge; Dr. Bob Young, consultant diabetologist and CMIO,
Diabetes and Endocrinology, Salford Royal Foundation NHS Trust; clinical
lead, National Diabetes Audit (NDA) and National Cardiovascular Intelligence
Network (NCVIN), Dr. Alison Elderfield and project manager, National
Paediatric Diabetes Audit Research and Policy Division; Royal College of
Paediatrics and Child Health, Dr Justin Warner, consultant in Paediatric
Endocrinology and Diabetes, honorary Senior Lecturer Cardiff University, and
clinical lead for the National Paediatric Diabetes Audit; and Dr. Fiona
Campbell, national clinical lead for the Children and Young People’s
Diabetes Network and Peer Review Quality Assurance Programme, NHS
England.
Mazarello Paes et al. Systematic Reviews  (2015) 4:159 Page 8 of 9Funding
This project is funded by UCL IMPACT/Department of Health PhD
Studentship 2014/15. This is an independent report commissioned and
funded by the Policy Research Programme in the Department of Health. The
views expressed are not necessarily those of the department.
Author details
1Institute of Child Health, University College London, London, UK. 2Institute
of Public Health, University of Cambridge, Cambridge, UK. 3Institute of
Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. 4University
of Liverpool, Liverpool, UK. 5Oxford Children’s Hospital, University of Oxford,
Oxford, UK.
Received: 21 September 2015 Accepted: 27 October 2015References
1. Lind M, Svensson A, Kosiborod M, Gudbjörnsdottir S, Pivodic A, Wedel H,
et al. Glycemic control and excess mortality in type 1 diabetes. N Engl J
Med. 2014;371(21):1972–82.
2. Livingstone SJ, Levin D, Looker HC, Lindsay RS, Wild SH, Joss N, et al.
Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008–2010.
JAMA. 2015;313(1):37–44.
3. Harjutsalo V, Forsblom C, Groop PH. Time trends in mortality in patients
with type 1 diabetes: nationwide population based cohort study. BMJ.
2011;343:d5364.
4. Patterson CC, Dahlquist G, Harjutsalo V, Joner G, Feltbower RG, Svensson J,
et al. Early mortality in EURODIAB population-based cohorts of type 1
diabetes diagnosed in childhood since 1989. Diabetologia.
2007;50(12):2439–42.
5. Edge JA, Ford-Adams ME, Dunger DB. Causes of death in children with
insulin dependent diabetes 1990–96. Arch Dis Child. 1999;81(4):318–23.
6. Fazeli Farsani S, Souverein PC, van der Vorst MM, Knibbe CA, de Boer A,
Mantel-Teeuwisse AK. Chronic comorbidities in children with type 1 diabetes: a
population-based cohort study. Arch Dis Child. 2015;100(8):763–8.
7. Froisland DH, Graue M, Markestad T, Skrivarhaug T, Wentzel-Larsen T,
Dahl-Jorgensen K. Health-related quality of life among Norwegian
children and adolescents with type 1 diabetes on intensive insulin
treatment: a population-based study. Acta Paediatr. 2013;102(9):889–95.
8. Persson S, Dahlquist G, Gerdtham UG, Steen Carlsson K. Impact of
childhood-onset type 1 diabetes on schooling: a population-based register
study. Diabetologia. 2013;56(6):1254–62.
9. Chief Medical Officer's annual report 2012: Our Children Deserve Better:
Prevention Pays 24 October 2013. Available from: https://www.gov.uk/
government/publications/chief-medical-officers-annual-report-2012-our-
children-deserve-better-prevention-pays
10. Cameron FJ, de Beaufort C, Aanstoot HJ, Hoey H, Lange K, Castano L, et al.
Lessons from the Hvidoere International Study Group on childhood
diabetes: be dogmatic about outcome and flexible in approach. Pediatr
Diabetes. 2013;14(7):473–80.
11. Tamayo T, Rosenbauer J, Wild SH, Spijkerman AM, Baan C, Forouhi NG, et al.
Diabetes in Europe: an update. Diabetes Res Clin Pract. 2014;103(2):206–17.
12. Patterson C, Guariguata L, Dahlquist G, Soltesz G, Ogle G, Silink M. Diabetes
in the young—a global view and worldwide estimates of numbers of
children with type 1 diabetes. Diabetes Res Clin Pract. 2014;103(2):161–75.
13. Stanescu DE, Lord K, Lipman TH. The epidemiology of type 1 diabetes in
children. Endocrinol Metab Clin North Am. 2012;41(4):679–94.
14. International Diabetes Federation. IDF diabetes atlas: 2013. https://
www.idf.org/diabetesatlas.
15. Harjutsalo V, Sjöberg L, Tuomilehto J. Time trends in the incidence of type 1
diabetes in Finnish children: a cohort study. Lancet. 2008;371(9626):1777–82.
16. DIAMOND. Incidence and trends of childhood type 1 diabetes worldwide
1990–1999. Diabet Med. 2006;23(8):857–66.
17. Patterson CC, Dahlquist GG, Gyurus E, Green A, Soltesz G. Incidence trends
for childhood type 1 diabetes in Europe during 1989–2003 and predicted
new cases 2005–20: a multicentre prospective registration study. Lancet.
2009;373(9680):2027–33.
18. Kanavos P, van de Aardweg S, Schurer W. Diabetes expenditure, burden of
disease and management in 5 EU countries. London: London School of
Economics Health; 2012.19. DCCT. The effect of intensive treatment of diabetes on the development
and progression of long-term complications in insulin-dependent diabetes
mellitus. The Diabetes Control and Complications Trial Research Group.
N Engl J Med. 1993;329(14):977–86.
20. Nordwall M, Arnqvist HJ, Bojestig M, Ludvigsson J. Good glycemic control
remains crucial in prevention of late diabetic complications—the Linkoping
Diabetes Complications Study. Pediatr Diabetes. 2009;10(3):168–76.
21. White NH, Sun W, Cleary PA, Tamborlane WV, Danis RP, Hainsworth DP,
et al. Effect of prior intensive therapy in type 1 diabetes on 10-year
progression of retinopathy in the DCCT/EDIC: comparison of adults and
adolescents. Diabetes. 2010;59(5):1244–53.
22. Hirose A, Furushima D, Yamaguchi N, Kitano S, Uchigata Y. Prediction of
retinopathy at 20 years after onset in younger-onset type 1 diabetes using
mean metabolic memory-free HbA1c values: the importance of using
HbA1c data of total, not partial, diabetes duration. Diabetes Care.
2013;36(11):3812–4.
23. Johnson SR, Cooper MN, Jones TW, Davis EA. Long-term outcome of insulin
pump therapy in children with type 1 diabetes assessed in a large
population-based case-control study. Diabetologia. 2013;56(11):2392–400.
24. Kahler P, Grevstad B, Almdal T, Gluud C, Wetterslev J, Vaag A, et al. Targeting
intensive versus conventional glycaemic control for type 1 diabetes mellitus: a
systematic review with meta-analyses and trial sequential analyses of
randomised clinical trials. BMJ Open. 2014;4(8):e004806.
25. Shah SC, Malone JI, Simpson NE. A randomized trial of intensive insulin
therapy in newly diagnosed insulin-dependent diabetes mellitus. N Engl J
Med. 1989;320(9):550–4.
26. Hershey T, Bhargava N, Sadler M, White NH, Craft S. Conventional versus
intensive diabetes therapy in children with type 1 diabetes: effects on
memory and motor speed. Diabetes Care. 1999;22(8):1318–24.
27. Franklin VL, Khan F, Kennedy G, Belch JJ, Greene SA. Intensive insulin
therapy improves endothelial function and microvascular reactivity in
young people with type 1 diabetes. Diabetologia. 2008;51(2):353–60.
28. Perlman K, Ehrlich RM, Filler RM, Albisser AM. Sustained normoglycemia in
newly diagnosed type I diabetic subjects. Short-term effects and one-year
follow-up. Diabetes. 1984;33(10):995–1001.
29. Fullerton B, Jeitler K, Seitz M, Horvath K, Berghold A, Siebenhofer A.
Intensive glucose control versus conventional glucose control for type 1
diabetes mellitus. Cochrane Database Syst Rev. 2014;2:Cd009122.
30. Wysocki T, Harris MA, Wilkinson K, Sadler M, Mauras N, White NH. Self-
management competence as a predictor of outcomes of intensive therapy or
usual care in youth with type 1 diabetes. Diabetes Care. 2003;26(7):2043–7.
31. Orchard TJ, Nathan DM, Zinman B, Cleary P, Brillon D, Backlund JY, et al.
Association between 7 years of intensive treatment of type 1 diabetes and
long-term mortality. JAMA. 2015;313(1):45–53.
32. Tamborlane WV, Beck RW, Bode BW, Buckingham B, Chase HP, Clemons R,
et al. Continuous glucose monitoring and intensive treatment of type 1
diabetes. N Engl J Med. 2008;359(14):1464–76.
33. Aiello LP. Diabetic retinopathy and other ocular findings in the diabetes
control and complications trial/epidemiology of diabetes interventions and
complications study. Diabetes Care. 2014;37(1):17–23.
34. Lachin JM, Orchard TJ, Nathan DM. Update on cardiovascular outcomes at
30 years of the diabetes control and complications trial/epidemiology of diabetes
interventions and complications study. Diabetes Care. 2014;37(1):39–43.
35. Nathan DM, Bayless M, Cleary P, Genuth S, Gubitosi-Klug R, Lachin JM, et al.
Diabetes control and complications trial/epidemiology of diabetes
interventions and complications study at 30 years: advances and
contributions. Diabetes. 2013;62(12):3976–86.
36. Cengiz E, Connor CG, Ruedy KJ, Beck RW, Kollman C, Klingensmith GJ, et al.
Pediatric diabetes consortium T1D new onset (NeOn) study: clinical outcomes
during the first year following diagnosis. Pediatr Diabetes. 2014;15(4):287–93.
37. Nordwall M, Abrahamsson M, Dhir M, Fredrikson M, Ludvigsson J, Arnqvist
HJ. Impact of HbA1c, followed from onset of type 1 diabetes, on the
development of severe retinopathy and nephropathy: the VISS study
(vascular diabetic complications in southeast Sweden). Diabetes Care.
2015;38(2):308–15.
38. Control DRGD, Complications Trial Research Group AclotDRGiafNTIS. Effect
of intensive diabetes treatment on the development and progression of
long-term complications in adolescents with insulin-dependent diabetes
mellitus: diabetes control and complications trial. J Pediatr. 1994;125(2):177–88.
39. Lawes T, Franklin V, Farmer G. HbA1c tracking and bio-psychosocial
determinants of glycaemic control in children and adolescents with type 1
Mazarello Paes et al. Systematic Reviews  (2015) 4:159 Page 9 of 9diabetes: retrospective cohort study and multilevel analysis. Pediatr
Diabetes. 2014;15(5):372–83.
40. Dovc K, Telic SS, Lusa L, Bratanic N, Zerjav-Tansek M, Kotnik P, et al.
Improved metabolic control in pediatric patients with type 1 diabetes: a
nationwide prospective 12-year time trends analysis. Diabetes Technol Ther.
2014;16(1):33–40.
41. Samuelsson U, Steineck I, Gubbjornsdottir S. A high mean-HbA1c value
3–15 months after diagnosis of type 1 diabetes in childhood is related to
metabolic control, macroalbuminuria, and retinopathy in early
adulthood—a pilot study using two nation-wide population based quality
registries. Pediatr Diabetes. 2014;15(3):229–35.
42. Edge JA, James T, Shine B. Persistent individual tracking within overall
improvement in HbA1c in a UK paediatric diabetes clinic over 15 years.
Diabet Med. 2010;27(11):1284–8.
43. Gerstl EM, Rabl W, Rosenbauer J, Grobe H, Hofer SE, Krause U, et al.
Metabolic control as reflected by HbA1c in children, adolescents and young
adults with type-1 diabetes mellitus: combined longitudinal analysis
including 27,035 patients from 207 centers in Germany and Austria during
the last decade. Eur J Pediatr. 2008;167(4):447–53.
44. National Paediatric Diabetes Audit Report 2011-12: Royal College of
Paediatrics and Child Health; 2013. Available from: http://www.hqip.org.uk/
assets/NCAPOP-Library/NCAPOP-2013-14/NPDA-report-2011-12-low-res-
FINAL.pdf.
45. Livingstone SJ, Looker HC, Hothersall EJ, Wild SH, Lindsay RS, Chalmers J,
et al. Risk of cardiovascular disease and total mortality in adults with type 1
diabetes: Scottish registry linkage study. PLoS Med. 2012;9(10):e1001321.
46. Evidence for Policy and Practice Information (EPPI) and Co-ordinating
Centre IoE, University of London. EPPI-Centre Methods for Conducting
Systematic Reviews. March 2007, Updated 2010: http://eppi.ioe.ac.uk/cms/
LinkClick.aspx?fileticket=hQBu8y4uVwI%3d.
47. Mazarello Paes V, Hesketh K, O’Malley C, Moore H, Summerbell C, Griffin S,
et al. Determinants of sugar-sweetened beverage consumption in young
children: a systematic review. Obes Rev. 2015;16(11):903–13.
48. Mazarello Paes V, Ong KK, Lakshman R. Factors influencing obesogenic
dietary intake in young children (0–6 years): systematic review of qualitative
evidence. BMJ Open. 2015;5(9):e007396.
49. Shaw RL, Larkin M, Flowers P. Expanding the evidence within evidence-
based healthcare: thinking about the context, acceptability and feasibility of
interventions. Evid Based Med. 2014;19(6):201–3.
50. Pace NL. Research methods for meta-analyses. Best Pract Res Clin
Anaesthesiol. 2011;25(4):523–33.
51. Ogilvie D, Fayter D, Petticrew M, Sowden A, Thomas S, Whitehead M, et al.
The harvest plot: a method for synthesising evidence about the differential
effects of interventions. BMC Med Res Methodol. 2008;8:8.
52. Lakshman R, Mazarello Paes V, Hesketh K, O’Malley C, Moore H, Ong K, et al.
Protocol for systematic reviews of determinants/correlates of obesity-related
dietary and physical activity behaviors in young children (preschool 0 to
6 years): evidence mapping and syntheses. Syst Rev. 2013;2:28.
53. Wijndaele K, Lakshman R, Landsbaugh JR, Ong KK, Ogilvie D. Determinants
of early weaning and use of unmodified cow’s milk in infants: a systematic
review. J Am Diet Assoc. 2009;109(12):2017–28.
54. Barnett I, Guell C, Ogilvie D. The experience of physical activity and the
transition to retirement: a systematic review and integrative synthesis of
qualitative and quantitative evidence. Int J Behav Nutrit Phys Act. 2012;9:97.
55. Thomas J, Harden A, Oakley A, Oliver S, Sutcliffe K, Rees R, et al. Integrating
qualitative research with trials in systematic reviews. BMJ. 2004;328(7446):1010–2.
56. National Paediatric Diabetes Audit Report 2010-11: Royal College of
Paediatrics and Child Health; 2012. Available from: http://www.rcpch.ac.uk/
system/files/protected/page/NPDA%20Annual%20Report_25%2009%
2012%20for%20web_0.pdf.
57. National Paediatric Diabetes Audit Report 2013-14: Royal College of
Paediatrics and Child Health; 2015. Available from: http://www.rcpch.ac.uk/
system/files/protected/page/Revised%20Sept%202014%20NPDA%20
Report%201%20FINAL.pdf.
58. National Paediatric Diabetes Audit Report 2012-13: Part 1; Care processes
and outcomes: Royal College of Paediatrics and Child Health. 2014.
Available from: http://www.rcpch.ac.uk/system/files/protected/page/
NPDA%202012-13%20Core%20Report%202nd%20FINAL%20v%203.3.pdf.59. Beck RW, Tamborlane WV, Bergenstal RM, Miller KM, DuBose SN, Hall CA,
et al. The T1D exchange clinic registry. J Clin Endocrinol Metab.
2012;97(12):4383–9.
60. Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, Gregg EW.
Achievement of goals in U.S. diabetes care, 1999–2010. N Engl J Med.
2013;368(17):1613–24.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
